Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
Articles > Article · 2019
Authors: Münevver ERDİNÇ, Eugene R. Bleecker, J. Mark FitzGerald, Gary T. Ferguson, Peter Barker, Stephanie Sproule, Richard F. Olsson, Ubaldo J. Martin, Mitchell Goldman
LANCET RESPIRATORY MEDICINE, Journal Indexed in SCI Expanded, International, 2019, vol 7, pp 46-59
DOI: 10.1016/s2213-2600(18)30406-5
Summary
Background Benralizumab is an interleukin-5 receptor a-directed cytolytic monoclonal antibody that has been shown to safely reduce exacerbations and improve lung function for patients with asthma. We assessed the long-term safety and efficacy of benralizumab for patients with severe, uncontrolled eosinophilic asthma.